Health TrialsbyHealthPanel

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

ConditionNon Small Cell Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHunan Province Tumor Hospital

About this trial

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology

Potentially Resectable NSCLC

Treatment Plan is Crizotinb or Standard Chemotherapy

Disqualifiers

Patients with contraindication of chemotherapy

Pregnant or breast feeding women

Trial population

Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

PFS

Progression free survival

Time frame
may 2020- may 2021 (1 year)

Secondary outcomes

1

OS

Overall survival

Time frame
may 2020- may 2021 (1 year)
2

ORR

To measure the patients's overall response rate

Time frame
may 2020- may 2021 (1 year)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Hunan Province Tumor Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now